AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01747811 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wavelength-2 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combined oral contraceptives (COC)
Description: A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Description: A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400mg
Description: A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cenerimod 0.5 mg
Description: This will be administered orally as a film-coated tablet in the morning.
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5 mg
Description: This will be administered orally as a film-coated tablet in the morning.
Study NCT02779868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: patients included in this group will take 4 capsules per day of olive oil.
Study NCT01059357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Robotic Transoral Robotic Surgical System
Description: (TORS) Da Vinci Robotic Transoral Robotic Surgical System
Study NCT01308840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Day 1 and 15 = 6 mg/kg IV
Study NCT01308840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Days 1 and 15 = 85mg/m2 IV
Study NCT02077920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride injection
Description: SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
Study NCT01308840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Days 1 and 15 = 1000 mg/m2 IV
Study NCT01082081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Paracetamol 1000 mg
Study NCT01082081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Description: Paracetamol 500 mg
Study NCT01082081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02175277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
Study NCT01980199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: 600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days
Study NCT04212130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCA method for assessing environmental cleanliness
Description: Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method
Study NCT02477917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot with Parietaria judaica pollen extract
Description: Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
Study NCT01202890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
Study NCT01202890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid, Doxil, Avastin
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
Study NCT02242058 — intervention group
Intervention type: OTHER
Intervention: Quantitative sensory testing
Study NCT03159468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
Study NCT03159468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
Study NCT03159468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Description: Participants consume an alcoholic beverage in the lab.
Study NCT02377414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban solution for Infusion
Description: Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
Study NCT02377414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
Study NCT02106182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)
Study NCT02106182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-days voiding diary
Description: 3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
Study NCT02106182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 weeks
Study NCT00936663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Study NCT00936663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Study NCT01769976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic fasting
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cenerimod 4 mg
Description: This will be administered orally as a film-coated tablet in the morning.
Study NCT02077920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Description: This will be administered orally as a film-coated tablet in the morning.
Study NCT04255277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal, activated
Description: Granules for oral suspension will be used and administered open-label.
Study NCT02077920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber bronchoscope
Description: For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
Study NCT04786145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis
Description: This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
Study NCT04786145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
Study NCT04786145 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No active treatment is given.
Study NCT01382212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
Study NCT02840500 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04002661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flibanserin
Description: Flibanserin tablet
Study NCT04002661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT00743483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBSSL
Description: oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
Study NCT03017495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg/mL oral solution
Study NCT03017495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Hard gelatin capsules for oral use at a strength of 25 mg
Study NCT01769976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction
Study NCT04255277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Study NCT01769976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy balance diet
Study NCT01769976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy balance diet
Study NCT01503814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular disease management
Description: This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)
Study NCT04357184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
Study NCT03076281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally
Study NCT03076281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Given orally
Study NCT03076281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin +Doxycycline
Description: Given orally
Study NCT04045782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: single arm
Description: switch from originator (Humira) to biosimilar (Imraldi)
Study NCT03266081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Description: topical anesthetic
Study NCT01426698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
Study NCT01426698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed cord clamping
Description: at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
Study NCT00894543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
Study NCT00894543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
Study NCT02622568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veregen only
Description: Topical application of Veregen 15% ointment on affected areas twice daily
Study NCT02622568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy and Veregen
Description: Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
Study NCT03425552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
Study NCT04011592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Description: single intravenous infusion of Ketamine (0.5 mg/kg)
Study NCT04426994 — intervention group
Intervention type: DRUG
Intervention: proton pump inhibitor use
Description: Patients using long term proton pump inhibitor
Study NCT04011592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Description: single intravenous infusion of Ketamine (0.2 mg/kg)
Study NCT03425552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
Study NCT03210896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Sub group I will drink Orange juice and have repeat measures.
Study NCT02390570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Capacity Assessment Instrument
Description: The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
Study NCT03470376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC)
Description: An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
Study NCT03470376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No nutraceutical combination (noNC)
Description: Prosecution of standardized diet regimen for 3 months
Study NCT02492516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: mesenchymal stem cells injection via peripheral vein.
Study NCT01970813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture and bee venom acupuncture point injection
Description: acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
Study NCT01970813 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture and normal saline injections
Description: sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
Study NCT02515071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study NCT02515071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study NCT01957852 — intervention group
Intervention type: OTHER
Intervention: FloSeal
Study NCT00884221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly purified menotrophin
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Study NCT00884221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FSH
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Study NCT02748122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MMT 723
Description: Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
Study NCT01993056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Study NCT01993056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: no FIFA 11+
Study NCT03032510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Study NCT05558488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meatless, restrictive ketogenic diet
Description: Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes.
Study NCT02126046 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: unrelated CB following haplo-identical hematopoietic stem cells transplantation
Study NCT03032510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study NCT03032510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03032510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03032510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT03032510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin